Highlights

  • Invion is developing Photosoft photodynamic therapy for cancer and selected other diseases.
  • An April 2026 clinical update reported additional safety findings from squamous cell carcinoma patients.
  • The trial safety review committee approved expansion to basal cell carcinoma participants.
  • The company is evaluating INV043 with a topical formulation in a Phase I/II study.
  • Clinical evidence, regulatory requirements and development funding remain key considerations.

Invion Limited (ASX:IVX) is an Australian clinical-stage life sciences company developing Photosoft photodynamic therapy (PDT) technology for cancer treatment. Its lead clinical programme uses the investigational photosensitiser INV043 in patients with non-melanoma skin cancer. An April 2026 announcement detailed findings from a further patient cohort and a decision to extend testing to basal cell carcinoma, widening the range of skin cancers assessed in the ongoing study.

Clinical Study Broadens Beyond Squamous Cell Carcinoma

In its 20 April 2026 announcement, Invion Limited (ASX:IVX) reported findings from another six patients with cutaneous squamous cell carcinoma. The company stated that no adverse effects or pain had been observed in that cohort. It also reported reductions in lesion size relative to baseline, with a statistical result of p<0.05, and complete resolution in selected cases. These are interim observations; the durability of responses was still being assessed.

Following its review of the available evidence, the study’s safety review committee authorised expansion to basal cell carcinoma patients. The decision does not constitute regulatory approval of INV043 or establish its effectiveness across broader patient populations. The Phase I/II study remains an important source of evidence about tolerability, treatment procedures and preliminary activity.

How Photosoft Photodynamic Therapy Works

Invion Limited (ASX:IVX) is investigating a treatment approach that combines a photosensitising compound with controlled light exposure. According to the company’s description of its Photosoft platform, light activation in the presence of oxygen generates reactive oxygen species that can damage targeted cells. Treatment outcomes depend on factors including compound delivery, light penetration and the characteristics of the tissue being treated.

The topical INV043 programme applies this mechanism to skin lesions. Photodynamic therapy differs from systemic medicines because activation occurs where appropriate light is delivered. However, localised application does not remove the need to assess adverse events, treatment consistency or the possibility of recurrence. Invion’s reported fluorescence signals are also relevant to the programme’s exploration of combined diagnostic and therapeutic properties.

Clinical Evidence and Programme Development

The 2026 update places emphasis on patient observations rather than a completed pivotal efficacy assessment. Invion Limited (ASX:IVX) still needs suitable clinical data to establish the treatment’s safety and efficacy in the intended patient groups. Decisions about study design, later-stage testing and submissions to regulators depend on the evidence generated and applicable regulatory requirements.

The company describes Photosoft as a platform with potential uses in multiple cancer indications. Nevertheless, findings from one formulation, administration route or disease setting should not automatically be applied to another. Skin cancer trial outcomes therefore need to be considered separately from work involving other cancers or non-cancer applications.

Development Risks and Operational Considerations

Clinical-stage drug development involves uncertainty about patient recruitment, comparative effectiveness, dose optimisation, manufacturing and regulatory review. For Invion Limited (ASX:IVX), the distinction between encouraging early-stage observations and outcomes confirmed in larger controlled studies is particularly important. Future development also requires expenditure, and the amount and timing of funding needs depend on the scale and progression of research activities.

Key Insights

Invion Limited (ASX:IVX) reported a 2026 expansion of its non-melanoma skin cancer study after further squamous cell carcinoma observations. The move to basal cell carcinoma testing adds a new clinical setting for INV043, while efficacy durability, larger-study evidence and regulatory assessment remain unresolved. The company’s reported progress should therefore be interpreted within the limitations of an ongoing early-stage clinical programme.